1.
Bioorg Med Chem Lett
; 22(24): 7518-22, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23122867
RESUMO
High throughput screening of the Roche compound collection led to the identification of diaminopyrroloquinazoline series as a novel class of PTP1B inhibitors. Structural modification of diaminopyrroloquinazoline series resulted in pyrido[2,3-d]pyrimidine-2,4-diamine series which was further optimized to give compounds 5 and 24 as potent, selective (except T-cell phosphatase) PTP1B inhibitors with good mouse PK properties.